newsfilter
← Earnings
Earnings Releases·

Kyntra Bio — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue rose to $1.8 million from $1.1 million in Q3 2025, while net income turned positive at $0.2 million compared to a $13.1 million loss the prior year; total liabilities decreased to $56.0 million from $115.1 million as of year-end 2025.
  • The company plans to initiate a pivotal Phase 3 trial for roxadustat in LR-MDS patients in Q1 2027, contingent on securing a strategic partnership or external capital raise.
  • Development of FG-3246 and FG-3180 was discontinued following insufficient efficacy, with management projecting over $20 million in operating expense savings for 2027 and 2028.
  • An amended royalty financing agreement reduced the maximum aggregate payment obligation to $65 million and will terminate once a $15 million cap is reached, allowing the company to retain all subsequent EVRENZO royalties in Astellas territories.
  • Cash, equivalents, investments, and receivables totaled $44.1 million as of September 30, 2026, with the company expecting this position to fund operations into 2028.
Company
KYNTRA BIO INC
Sector
Healthcare
Industry
Biotechnology